Bill Ackman Says Valeant (VRX) Now 'Classic' Pershing Square Investment - CNBC

August 26, 2016 8:15 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Bill Ackman says Valeant Pharma (NYSE: VRX) has made a lot of progress and that a passive position was a "mistake," according to commentary on CNBC today. The investor says Valeant is now a "classic" Pershing Square investment.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Hedge Funds, Trader Talk

Related Entities

William Ackman, Pershing Square Capital

Add Your Comment